Lipid-Polymer Hybrid Nanoparticles for Controlled Delivery of Hydrophilic and Lipophilic Doxorubicin for Breast Cancer Therapy [Erratum]

This article refers to:

Lipid-polymer hybrid nanoparticles for controlled delivery of hydrophilic and lipophilic doxorubicin for breast cancer therapy

Tahir N, Madni A, Correia A, et al. Int J Nanomed. 2019;14:4961–4974.

On page 4967, Figure 3 artwork is incorrect, Figure 4 artwork was mistakenly added by the Editorial staff during the publication process. The correct figure is:

Following feedback from a reader, we found the incorrect artwork was presented for Figure 3.

Figure 3 FTIR spectra of PLGA (A), lecithin (B), DSPE-PEG 2000 (C), Luterol (D), DOX (E) blank formulation (F), and DOX loaded LPHNPS (G).

Abbreviations: DOX, doxorubicin; DSPE-PEG 2000, 1,2-distearoyl-Sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)]-2000; LPHNPs, lipid polymer hybrid nanoparticles; PLGA, poly (D, L-lactide-co-glicolide).